EXDENSUR — 2149712
Application number
2149712
Registration number
TMA1188770
International Registration Number
1628399
Type(s)
Standard Characters
Category
Trademark
CIPO Status
REGISTERED
TM5 status
LIVE/REGISTRATION/Issued
and Active
The trademark application has been registered with the Office.
Filed
2021-10-07
International Registration
2021-10-07
Registered
2023-07-05
Registration Expiry Date
2031-10-07
Registered Owner
Glaxo Group Limited
GSK Medicines Research Centre
Gunnels Wood Road, Stevenage SG1 2NY
UNITED KINGDOM
Agent
BORDEN LADNER GERVAIS LLP
World Exchange Plaza
100 Queen Street, Suite 1300
Ottawa
ONTARIO K1P1J9
Documents
Index headings
- EXDENSUR
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations for the treatment of viral conditions namely human immunodeficiency virus (HIV), HPV, RSV, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain, bone pain and fatigue; pharmaceutical preparations for the treatment of blood-related diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, sports injuries, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and skin structure infections namely bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and sexually transmitted diseases; pharmaceutical preparations for the treatment of hormonal related diseases and disorders namely hypogonadism, testosterone/androgen disorders and estrogen disorders; pharmaceutical preparations for the treatment of gastrointestinal related diseases and disorders namely irritable bowel disorders and symptoms, digestive disorders and acid-related disorders; pharmaceutical preparations for the treatment of sexual dysfunction namely erectile dysfunction, male and female sexual dysfunction disorders namely arousal disorder, pain disorder, desire disorder and orgasm disorder; pharmaceutical preparations for the treatment of genitourinary diseases namely urological diseases and disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrheal and infertility; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of sexually transmitted diseases, inflammatory pelvic diseases, vasomotor/menopausal symptoms, endometriosis/uterine fibroids, Leiomyoma, endourology/stone, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of prostatitis, nephritis, cystitis, vaginitis, renal disease; pharmaceutical preparations for the treatment of premenstrual dysphoric disorder, premenstrual syndrome, male hypogonadism and hormonal disorders namely polycystic ovary syndrome; pharmaceutical preparations for the treatment of hepatological related diseases namely hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, and cirrhosis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia (male pattern baldness); pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses; pharmaceutical preparations for the treatment of damaged skin and tissue namely bee stings, sunburn, rashes, sores, corns, calluses and acne; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; allergy medications; vaccines, namely prophylactic and therapeutic vaccines for humans; pharmaceutical preparations for the treatment of neurological diseases and disorders namely Parkinsons disease, Alzheimers disease, Huntingtons disease, dementia, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory-related pain, fibromyalgia, stroke, multiple sclerosis, insomnia; pharmaceutical preparations for the treatment of central nervous system diseases and disorders namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, depression and anxiety and their related disorders namely schizophrenia and psychoses; pharmaceutical preparations for the treatment of muscular dystrophy.
Claims
- Priority Filing Date: July 07, 2021, Country or Office: UNITED KINGDOM, Application No. UK00003665736 in association with the same kind of goods
Recordals (known also as Footnotes)
CHANGE IN TITLE / CHANGEMENT EN TITRE: TYPE OF CHANGE / GENRE DE CHANGEMENT: Name and Address / Nom et adresse DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2023-07-26 DATE OF CHANGE / DATE DE CHANGEMENT: 2023-06-28 COMMENTS / COMMENTAIRES: From: Glaxo Group Limited To: Glaxo Group LimitedAction History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2021-10-07 | Registration | |
| International Registration | 2021-10-07 | 2031-10-07 | |
| Created | 2021-11-24 | ||
| Formalized | 2021-11-24 | ||
| Designation Notification - Madrid Protocol | 2021-11-25 | 2023-05-25 | |
| Notification of Possible Opposition Sent | 2022-09-26 | ||
| Agent Changed | 2023-01-21 | From/De: To/A: 4 | |
| Search Recorded | 2023-03-14 | ||
| Approved | 2023-03-20 | APPROVED BY PROGRAM EX200M1 | |
| Approval Notice Sent | 2023-03-20 | APPROVED BY PROGRAM EX200M1 | |
| Advertised | 2023-04-12 | Vol.70 Issue 3572 | |
| Opposition Start Date Notice Sent | 2023-04-12 | Requested on 2023/04/12 03:30:24 in program jr500m1 | |
| Registration Pending | 2023-07-05 | ||
| Registered | 2023-07-05 | ||
| Statement of Grant of Protection Sent | 2023-07-05 | ||
| Amendment to Registration | 2023-07-27 | DP:2023-07-26 Effective Date: 2023-06-28 |